Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Innovation Council · Running

StentGuard Clinical validation of the First Implantable Sensor System for Wireless detection of stent occlusion/ restenosis

Coordinator
Vesselsens GmbH, Germany
Runs
1 October 2022 to 31 July 2025
Status
Running
EU funding
€2.5m
Total cost
€11.3m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190107486

What the project is doing

In the project's own words, from its summary on CORDIS.

Globally, over 237 million people suffer from peripheral artery disease (PAD), an abnormal narrowing of the arteries. The implantation of stents (spiral wire protheses) is the first-line therapy for PAD with ~ 3.5M stents implanted worldwide every year. Restenosis, the gradual reclogging of the blood vessel after stent implantation, is a major problem leading to high morbidity and mortality which occurs within 6 years after implantation in ~23 % of all cases and is often detected when it is too late.

More frequent surveillance of PAD patients to avoid unnecessary amputations and death is an unmet clinical challenge. VesselSens is developing the StentGuard, a smart therapeutic monitoring device that enables rapid, low cost, early diagnosis of restenosis non-invasively and reliably. This device allows stent monitoring at high frequencies with low cost by non-specialist medical practitioners solving the problem of unchecked disease progression and saving the EU economy over €1bn/ year.

Topics

Who is involved

OrganisationCityCountryRole
Vesselsens GmbHBonnGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI